{"id":18796,"date":"2021-08-24T09:35:02","date_gmt":"2021-08-24T07:35:02","guid":{"rendered":"https:\/\/idibell.cat\/?p=18796"},"modified":"2021-08-24T09:58:06","modified_gmt":"2021-08-24T07:58:06","slug":"nous-biomarcadors-de-diagnostic-i-noves-dianes-terapeutiques-per-a-la-malaltia-minoritaria-limfangioleiomiomatosi","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2021\/08\/nous-biomarcadors-de-diagnostic-i-noves-dianes-terapeutiques-per-a-la-malaltia-minoritaria-limfangioleiomiomatosi\/","title":{"rendered":"Nous biomarcadors de diagn\u00f2stic i noves dianes terap\u00e8utiques per a la malaltia minorit\u00e0ria Limfangioleiomiomatosi"},"content":{"rendered":"<p>La Limfangioleiomiomatosi (LAM) \u00e9s una malaltia minorit\u00e0ria que afecta principalment a les dones i que es caracteritza per la proliferaci\u00f3 anormal de c\u00e8l\u00b7lules epitelials i fusiformes. Tot i que no es considera un c\u00e0ncer pr\u00f2piament dit, aquestes c\u00e8l\u00b7lules tenen la capacitat de generar met\u00e0stasi. A m\u00e9s, la hiperproliferaci\u00f3 pot danyar el teixit pulmonar i acabar en una insufici\u00e8ncia respirat\u00f2ria severa.<\/p>\n<p>El <a href=\"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/cancer-de-mama\/\">grup de recerca en c\u00e0ncer de mama<\/a> de l&#8217;Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (<a href=\"https:\/\/idibell.cat\/\">IDIBELL<\/a>) i del programa ProCURE de l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (<a href=\"http:\/\/ico.gencat.cat\/ca\/inici\">ICO<\/a>), liderat pel Dr. Miquel \u00c0ngel Pujana, ha identificat diferents productes de la transformaci\u00f3 de la histamina, una important mol\u00e8cula de senyalitzaci\u00f3 involucrada en m\u00faltiples funcions fisiol\u00f2giques, com a possibles biomarcadors per a millorar el diagn\u00f2stic de la malaltia, i tamb\u00e9, com a possibles noves dianes terap\u00e8utiques.<\/p>\n<p>El diagn\u00f2stic actual de la LAM \u00e9s cr\u00edtic, ja que presenta una elevada heterogene\u00eftat de s\u00edmptomes i nombroses similituds amb altres patologies. Fins ara, el diagn\u00f2stic diferencial es feia a trav\u00e9s dels nivells plasm\u00e0tics de VEGF-D. No obstant aix\u00f2, es tracta d&#8217;un biomarcador poc clar per l&#8217;elevada variabilitat interindividual, i en moltes ocasions calia arribar a la bi\u00f2psia del pulm\u00f3 per assegurar.<\/p>\n<p>En l&#8217;article publicat a l&#8217;<a href=\"https:\/\/www.embopress.org\/doi\/full\/10.15252\/emmm.202113929\"><em>EMBO Molecular Medicine<\/em><\/a>, els cient\u00edfics han identificat que les pacients amb LAM tenen nivells elevats en plasma d&#8217;un dels principals productes de la transformaci\u00f3 de la histamina, el MIAA, i que per tant, es podria utilitzar com a nou biomarcador. Carmen Herranz, investigadora de l\u2019IDIBELL i primera autora del treball comenta: &#8220;<em>Els nivells en plasma de MIAA s\u00f3n independents dels nivells del biomarcador utilitzat fins al moment, VEGF-D, i, per tant, l&#8217;opci\u00f3 m\u00e9s interessant seria utilitzar la combinaci\u00f3 de tots dos per a fer un diagn\u00f2stic fiable de la LAM<\/em>&#8220;.<\/p>\n<p>Hi ha pacients que no toleren b\u00e9 el tractament habitual per la LAM amb rapamicina, incl\u00fas algunes segueixen perdent funci\u00f3 pulmonar tot i la ter\u00e0pia. En aquest estudi, els investigadors han detectat que, en models animals, la inhibici\u00f3 de la via de la histamina atura la progressi\u00f3 de la malaltia. El Dr. Miquel \u00c0ngel Pujana explica que &#8220;<em>el tractament amb antihistam\u00ednics, f\u00e0rmacs ja aprovats per a altres patologies, \u00e9s benefici\u00f3s com a monoter\u00e0pia i incl\u00fas podria tenir un efecte sin\u00e8rgic amb la rapamicina<\/em>&#8220;. I afegeix: &#8220;<em>Ara hem comen\u00e7at un assaig cl\u00ednic per determinar l&#8217;efic\u00e0cia i seguretat del doble tractament amb rapamicina i loratidina, un antihistam\u00ednic com\u00fa<\/em>&#8220;.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Seg\u00fcents passos<\/strong><\/p>\n<p>L\u2019estudi publicat ha donat lloc a un assaig cl\u00ednic multic\u00e8ntric de fase II liderat per la Dra. Mar\u00eda Molina, tamb\u00e9 investigadora de l\u2019IDIBELL i cap de la Unitat Funcional d\u2019Interstici Pulmonar de l\u2019Hospital Universitari de Bellvitge. Aquest assaig est\u00e0 finan\u00e7at per l\u2019Instituto de Salud Carlos III i s\u2019iniciar\u00e0 en breu amb l\u2019objectiu d\u2019avaluar la seguretat i benefici de la combinaci\u00f3 de rapamicina i l\u2019antihistam\u00ednic loratadina en el tractament de LAM. Aix\u00ed mateix, s\u2019avaluaran els nous biomarcadors identificats de la malaltia.<\/p>\n<p>Aquest treball ha estat possible gr\u00e0cies a la participaci\u00f3 de les pacients LAM i el suport obtingut pel conveni de col\u00b7laboraci\u00f3 establert entre l&#8217;ICO i l&#8217;IDIBELL, i l&#8217;Associaci\u00f3 Espanyola de LAM (<a href=\"http:\/\/www.aelam.org\/\">AELAM<\/a>).<\/p>\n<p>Per altra banda, tamb\u00e9 han tingut un paper destacat en l\u2019estudi investigadors\/es de la Universitat Rovira i Virgili \u2013 IISPV (Dr. Oscar Yanes), responsables cl\u00ednics del LAM en diferents centres de refer\u00e8ncia estatals (Dra. Mar\u00eda Molina-Molina, Hospital Universitari de Bellvitge; Dra. Berta S\u00e1ez i Dr. Antonio Rom\u00e1n, Hospital Universitari de la Vall d\u2019Hebron; Dra. Cl\u00e0udia Valenzuela i Dr. Julio Ancochea, Hospital Universitari de La Princesa; Dra. Piedad Ussetti i Dra. Rosal\u00eda Laporta, Hospital Universitari Cl\u00ednica Puerta del Hierro; Dr. Jos\u00e9 A. Rodr\u00edguez-Portal, Hospital Universitari Virgen del Roc\u00edo; i Dr. \u00c1lvaro Casanova, Hospital Universitari d\u2019Henares), i investigadores de l\u2019ILD Center of Excellence St. Antonius Hospital dels Pa\u00efsos Baixos, del National Lung Disease Research Institute de Pol\u00f2nia, i del National Centre for Lymphangioleiomyomatosis del Regne Unit.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un estudi de l&#8217;IDIBELL i l&#8217;ICO, amb la col\u00b7laboraci\u00f3 de l&#8217;Associaci\u00f3 Espa\u00f1ola de LAM, ha detectat que les pacients que pateixen Limfangioleiomiomatosi (LAM) tenen nivells elevats en plasma d&#8217;un derivat de la histamina, el que es podria utilitzar per al diagn\u00f2stic de la malaltia.<\/p>\n","protected":false},"author":8,"featured_media":18797,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,390,447,452],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-10 06:39:37","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/18796"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=18796"}],"version-history":[{"count":2,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/18796\/revisions"}],"predecessor-version":[{"id":18799,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/18796\/revisions\/18799"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/18797"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=18796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=18796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=18796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}